



## Final Appraisal Recommendation

Advice No: 2513 – October 2013

**Pazopanib (Votrient®) 200 mg and 400 mg film-coated tablets**

**Submission by Novartis Pharmaceuticals**

### Recommendation of AWMSG

**Pazopanib (Votrient®) is recommended as an option for use within NHS Wales for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.**

#### Additional notes:

- The PALETTE study included patients whose disease had progressed on or after, or been intolerant to an anthracycline-based regimen.
- AWMSG acknowledged that the AWMSG criteria for appraising life-extending, end-of-life medicines did not apply to pazopanib (Votrient®) for the indication under consideration. An additional extension to life of at least three months compared to current NHS treatment was not demonstrated.
- AWMSG acknowledged that pazopanib (Votrient®) did not satisfy the AWMSG criteria for ultra orphan drug status.
- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 549), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	GlaxoSmithKline
Date of first issue	October 2013
Last reviewed	December 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2513:  
Pazopanib (Votrient<sup>®</sup>) 200 mg and 400 mg tablets. October 2013

